(Q33404622)

English

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195022%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195022%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

atypical hemolytic uremic syndrome

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195022%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Richard J Smith

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195022%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Christie Thomas

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195022%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

author name string

L Xie

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195022%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

C M Nester

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195022%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Y Zhang

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195022%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

language of work or name

0 references

publication date

1 December 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195022%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Transplantation Proceedings

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195022%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

44

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195022%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195022%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

3037-3040

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195022%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Atypical hemolytic-uremic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Complement regulatory genes and hemolytic uremic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Eculizumab for Atypical Hemolytic–Uremic Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Transplantation in atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Hemolytic uremic syndrome recurrence after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Combined kidney and liver transplantation for familial haemolytic uraemic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Liver-kidney transplantation to cure atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Causes of alternative pathway dysregulation in dense deposit disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Complement and the atypical hemolytic uremic syndrome in children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.07.141

7 January 2021

Identifiers

10.1016/J.TRANSPROCEED.2012.07.141

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195022%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195022%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33404622&oldid=1983915137"